AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 132 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.62 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $26,785,000 | +3625.3% | 777,492 | +2165.8% | 0.10% | +3400.0% |
Q3 2019 | $719,000 | -56.4% | 34,314 | -53.5% | 0.00% | -50.0% |
Q1 2019 | $1,649,000 | +265.6% | 73,779 | +345.8% | 0.01% | +200.0% |
Q3 2018 | $451,000 | +202.7% | 16,550 | +199.0% | 0.00% | +100.0% |
Q2 2018 | $149,000 | – | 5,536 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,295,712 | $47,524,000 | 3.98% |
Samsara BioCapital, LLC | 232,571 | $3,354,000 | 1.93% |
Eventide Asset Management | 3,851,000 | $55,531,000 | 1.80% |
Burrage Capital Management LLC | 112,546 | $1,609,000 | 1.58% |
Avidity Partners Management LP | 408,000 | $5,883,000 | 0.81% |
RICE HALL JAMES & ASSOCIATES, LLC | 982,484 | $14,167,000 | 0.79% |
Bullseye Asset Management LLC | 43,374 | $626,000 | 0.75% |
Nantahala Capital Management | 1,005,302 | $14,496,000 | 0.54% |
ARMISTICE CAPITAL, LLC | 600,000 | $8,652,000 | 0.54% |
Values First Advisors, Inc. | 27,042 | $389,947 | 0.47% |